Migraine and neuropeptides

Tajti, János; Delia, S.; Majláth, Zsófia; Tuka, Bernadett; Csáti, Anett; Vécsei, László

doi:10.1016/j.npep.2015.03.006

Cited by 108 publications

(88 citation statements)

References 191 publications

(261 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time, the reaction time of mice to cold or hot stimulation was decreased after the application of NTG, most obviously in 4 hr. The expression levels of two pain‐related peptides, CGRP and NPY , in serum were increased by NTG. While the mouse head discomforts, the pain threshold decrease and the elevation of CGRP and NPY levels in serum were all attenuated by the VP administration, suggesting that VP played a protective role against migraine‐caused neural damage in NTG‐injected mice.…”

Section: Discussionmentioning

confidence: 99%

Valproate Plays a Protective Role against Migraine by Inhibiting Protein Kinase C Signalling in Nitroglycerin‐treated Mice

Chen

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Migraine is a common disease with a high morbidity. Valproate (VP) is used as an anti-epilepsy drug in clinic. This study aimed to investigate the role of VP in nitroglycerin (NTG)-induced migraine using a mouse model. NTG was employed by intraperitoneal injection to induce a migraine model in mice. The NTG administration caused mouse head discomforts, decreased tolerance to cold or hot stimulation and increased content of nitric oxide, calcitonin gene-related peptide and neuropeptide Y in serum, which were ameliorated by intraperitoneal injection of VP. The levels of two inflammatory factors, interleukin (IL)-1β and inducible nitric oxide synthase, in dura mater were increased by NTG treatment, while the increase was attenuated by application of VP. In addition, the phosphorylation levels of protein kinase C (PKC) α, γ, δ and ε were increased by NTG and decreased by VP. However, their total expression at the transcriptional and translational levels did not change significantly. Two substrates of PKC, cAMP-response element binding protein 1 and signal transducer and activator of transcription 1 were also phosphorylated by NTG application, and the phosphorylation level was attenuated by VP, consistent with the change of PKC informs. Together, we demonstrated that VP prevented damage due to migraine by inhibiting PKC signalling in NTG-injected mice, which may provide a basis for investigating the clinical treatment of migraine.

show abstract

Section: Discussionmentioning

confidence: 99%

Valproate Plays a Protective Role against Migraine by Inhibiting Protein Kinase C Signalling in Nitroglycerin‐treated Mice

Chen

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Beta-blockers (metoprolol, propranolol), calcium channel blockers (flunarizine), antiepileptic drugs (valproic acid, topiramate) or antidepressants (amitriptyline, venlafaxine) are recommended for migraine prevention [19]. Lately Botulinum toxin A (BoNTA) has proven to be effective and it improves the quality of life in chronic migraine treatment [28][29][30][31]. An important disadvantage of BoNTA is its route of administration: intramuscular injection in the muscles of the face and neck [28,30].…”

Section: Migrainementioning

confidence: 99%

“…picture of an 'inflammatory state' [33,34]. Neurogenic inflammation is presumed to be an important factor in various neurological diseases: brain injury [35] , neuropathic pain [36], epilepsy [37,38] and primary headache diseases [39].…”

Section: Neurogenic Inflammationmentioning

confidence: 99%

Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects

Lukács

Tajti

Fülöp

et al. 2017

CMC

View full text Add to dashboard Cite

Abstract:Background: Migraine is a primary headache disorder. Despite numerous studies conducted with the aim to understand the pathophysiology of migraine, several aspects are still unclear. The trigeminovascular system plays a key role. Neurogenic inflammation is presumed to be an important factor in migraine pathophysiology, mediated by the activation of primary neurons, leading to the release of various pro-inflammatory neuropeptides and neurotransmitters such as Calcitonin Gene-Related Peptide (CGRP), substance P (SP), and vasoactive intestinal peptide (VIP). Nitric oxide (NO), Pituitary adenylate cyclase-activating polypeptide (PACAP) and Glutamate (Glu) also play an important role in the modulation of inflammatory mechanisms. Objective: To review the literature focusing on novel therapeutic targets in migraine, related to neurogenic inflammation. Method: A systematic literature search in the database of PUBMED was conducted regarding therapeutic strategies in migraine, focusing on substances and cytokines released during neurogenic inflammation, published in January 2017. Results: Ongoing phase III clinical studies with monoclonal antibodies against CGRP and CGRP receptors offer promising novel aspects for migraine treatment. Preclinical and clinical studies targeting SP and nitric oxide synthase (NOS) were all terminated with no significant result compared to placebo. New promising therapeutic goal could be PACAP and its receptor (PAC 1 ), and kynurenic acid (KYNA) analogues. Conclusion: Current migraine treatment offers pain relief only for a small proportion of migraine patients and might not be adequate for patients with cardiovascular comorbidity due to side effects. Better understanding of migraine pathophysiology might, therefore, lead to novel therapeutic lines both in migraine attack treatment and prophylaxis.

show abstract

“…For example, inadequate regulation of the autonomic nervous system (ANS) (Ebinger et al, 2006, Geraud and Donnet, 2013, Melek et al, 2007), derangement of serotonin metabolism (Dussor, 2014, Hoffmann and Goadsby, 2014, Vollbracht and Rapoport, 2014), insensitive reaction to reduced oxygen in the vasculature and tissue (Friberg et al, 1994, Lacombe et al, 1992, Raddant and Russo, 2014), disruption of the normal pain pathways (Kroger and May, 2015), peculiar platelet metabolism (Danese et al, 2014, Gawel and Rose, 1982, Hanington, 1989), neurogenic inflammation (Tajti et al, 2015) and etc. (Alstadhaug, 2014).…”

Section: Introductionmentioning

confidence: 99%

Resting-state fMRI study of acute migraine treatment with kinetic oscillation stimulation in nasal cavity

Wang

Hallin

et al. 2016

NeuroImage: Clinical

View full text Add to dashboard Cite

Kinetic oscillatory stimulation (KOS) in the nasal cavity is a non-invasive cranial nerve stimulation method with promising efficacy for acute migraine and other inflammatory disorders. For a better understanding of the underlying neurophysiological mechanisms of KOS treatment, we conducted a resting-state functional magnetic resonance imaging (fMRI) study of 10 acute migraine patients and 10 normal control subjects during KOS treatment in a 3 T clinical MRI scanner. The fMRI data were first processed using a group independent component analysis (ICA) method and then further analyzed with a voxel-wise 3-way ANOVA modeling and region of interest (ROI) of functional connectivity metrics.All migraine participants were relieved from their acute migraine symptoms after 10–20 min KOS treatment and remained migraine free for 3–6 months. The resting-state fMRI result indicates that migraine patients have altered intrinsic functional activity in the anterior cingulate, inferior frontal gyrus and middle/superior temporal gyrus. KOS treatment gave rise to up-regulated intrinsic functional activity for migraine patients in a number of brain regions involving the limbic and primary sensory systems, while down regulating temporally the activity for normal controls in a few brain areas, such as the right dorsal posterior insula and inferior frontal gyrus.The result of this study confirms the efficacy of KOS treatment for relieving acute migraine symptoms and reducing attack frequency. Resting-state fMRI measurements demonstrate that migraine is associated with aberrant intrinsic functional activity in the limbic and primary sensory systems. KOS in the nasal cavity gives rise to the adjustment of the intrinsic functional activity in the limbic and primary sensory networks and restores the physiological homeostasis in the autonomic nervous system.

show abstract

Migraine and neuropeptides

Cited by 108 publications

References 191 publications

Valproate Plays a Protective Role against Migraine by Inhibiting Protein Kinase C Signalling in Nitroglycerin‐treated Mice

Valproate Plays a Protective Role against Migraine by Inhibiting Protein Kinase C Signalling in Nitroglycerin‐treated Mice

Migraine, Neurogenic Inflammation, Drug Development - Pharmacochemical Aspects

Resting-state fMRI study of acute migraine treatment with kinetic oscillation stimulation in nasal cavity

Contact Info

Product

Resources

About